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Abstract
Aim: Traumatic events are involved in the development and maintenance of psychotic
symptoms. There are few trials exploring trauma-focused treatments as interventions
for psychotic symptoms, especially in individuals with early psychosis. This trial will eval-
uate the feasibility and acceptability of conducting a definitive trial of Eye Movement
Desensitization and Reprocessing for psychosis (EMDRp) in people with early psychosis.
Methods: Sixty participants with first episode psychosis and a history of a traumatic/
adverse life event(s)will be recruited from early intervention services in the North
West of England and randomized to receive16 sessions of EMDRp + Treatment as
Usual (TAU) or TAU alone. Participants will be assessed at baseline, 6 and 12 months
post-randomization using several measures of psychotic symptoms, trauma symp-
toms, anxiety, depression, functioning, service-user defined recovery, health econom-
ics indicators and quality of life. Two nested qualitative studies to assess participant
feedback of therapy and views of professional stakeholders on the implementation
of EMDRp into services will also be conducted. The feasibility of a future definitive
efficacy and cost-effectiveness evaluation of EMDRp will be tested against several
outcomes, including ability to recruit and randomize participants, trial retention at 6-
and 12-month follow-up assessments, treatment engagement and treatment fidelity.
Conclusions: If it is feasible to deliver a multi-site trial of this intervention, it will be
possible to evaluate whether EMDRp represents a beneficial treatment to augment
existing evidence-based care of individuals with early psychosis supported by early
intervention services.
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1 | INTRODUCTION
Psychotic disorders are a major cause of personal and societal burden
affecting approximately 0.7% of the population (McManus,
Bebbington, Jenkins, & Brugha, 2016; Finberg et al., 2013). They are
associated with long-term disability (Wiersma et al., 2000), heightened
mortality and risk of suicide (Palmer, Pankratz, & Bostwick, 2005;
Saha, Chant, & McGrath, 2007) and reduced recovery outcomes
(Jääskeläinen et al., 2013). Recommended pharmacological and psy-
chological interventions (NICE, 2014) can be effective, but response
to treatment is modest and variable (e.g., Jauhar et al., 2014; Wykes,
Steel, Everitt, & Tarrier, 2008). In addition, patients prescribed anti-
psychotic medications have relatively low rates of adherence, with
approximately only two thirds of medication prescribed actually being
taken (Cramer & Rosenheck, 2006). This may be due at least in part to
marked and diverse profile of severe side-effects (Young, Taylor, &
Lawrie, 2015). Cognitive Behaviour Therapy has consistent but small
to moderate effects on positive symptoms only (Bighelli et al., 2018;
McKenna, Leucht, Jauhar, Laws, & Bighelli, 2019). Therefore, further
work is required in order to improve outcomes.
Approximately 80% of patients with psychosis have a history of
traumatic life experiences (de Bont et al., 2015; Hardy et al., 2016).
Meta-analyses indicate that trauma is associated with an increased
risk of developing psychosis, and heightened severity of psychotic
symptoms in those who already have psychosis (e.g., Beards
et al., 2013; Varese et al., 2012).The prevalence of trauma and post-
traumatic symptoms is particularly marked in individuals with early
psychosis (e.g., Rodrigues & Anderson, 2017), possibly due to addi-
tional traumatogenic experiences that many people with psychosis
are exposed to in the early stages of the illness (e.g., coerced treat-
ment, loss of employment and relationships, the experience of terrify-
ing symptoms). In addition, a range of trauma sequalae, such as
dissociation and intrusive memories/flashbacks, are involved in the
maintenance of psychotic symptoms (Hardy et al., 2016; Varese,
Barkus, & Bentall, 2012; Williams, Bucci, Berry, & Varese, 2018). Clini-
cal guidelines (e.g., NICE, 2014) have recognized both the need for
routine trauma assessment in people with first episode psychosis as
well as the need for further evaluation of the efficacy and acceptabil-
ity of trauma-focused therapies for this group.
The treatment of trauma in people with psychosis has largely been
ignored until recent years. Psychotic symptoms have been used as an
exclusion criterion in 93% of existing trauma-focused intervention trials
(Meyer, Farrell, Kemp, Blakey, & Deacon, 2014; Ronconi, Shiner, &
Watts, 2014), despite the fact that a substantial minority of patients
with psychosis also meet the criteria for Post-Traumatic Stress Disorder
(PTSD) and many more report subsyndromal, but nonetheless dis-
tressing, trauma symptoms (de Bont et al., 2015). Because of this, there
has been recent interest in evaluating trauma-focused therapies in this
patient group. Eye Movement Desensitization and Reprocessing
(EMDR) is, alongside Trauma-Focused Cognitive Behavioural Therapy
(TF-CBT), one of the trauma-focused therapies that has received exten-
sive empirical scrutiny in the last three decades (Bisson et al., 2007;
Bisson, Roberts, Andrew, Cooper, & Lewis, 2013). EMDR is endorsed
as a recommended intervention for PTSD in several clinical guidelines
worldwide (e.g., ISTSS, 2019; NICE, 2018; World Health
Organization, 2013) and recent health economic evaluations have
attested to its cost-effectiveness relative to other trauma-focused
approaches (Mavranezouli et al., 2020). Trials investigating the efficacy
of EMDR and other trauma-focused therapies in people with severe
mental illness and PTSD have been encouraging (Sin, Spain, Furuta,
Murrells, & Norman, 2017). A large-scale RCT in the Netherlands com-
pared the efficacy of EMDR, prolonged exposure (PE) and treatment as
usual in individuals with psychosis and comorbid PTSD. Patients receiv-
ing PE (56.6%; p = .006) or EMDR (60.0%; p < .001) were more likely to
achieve loss of PTSD diagnosis compared to TAU (27.7%; van den Berg
et al., 2015). Both treatments were safe and acceptable, and gains were
maintained at 6 months follow-up assessments. Secondary analyses
indicated that there were significant reductions in symptoms of psycho-
sis in people who received these interventions (de Bont et al., 2016)
but conclusions drawn are limited as the trials were not designed to
assess change in psychotic symptoms.
Although EMDR is already being successfully adapted to treat mental
health difficulties other than PTSD in people with a trauma history (Novo
et al., 2014;Wood & Ricketts, 2013), previous psychosis trials have exclu-
sively evaluated EMDR as a treatment for comorbid PTSD in people with
long-standing psychotic disorders. The current trial addresses priorities
identified by previous systematic reviews on the application of trauma-
focused therapy in people with psychosis (Sin & Spain, 2017; Sin
et al., 2017; Swan, Keen, Reynolds, & Onwumere, 2017), in particular
(1) whether EMDR can be used safely and effectively in patients with
recent onset psychosis and patients with trauma symptoms that do not
necessarily meet diagnostic thresholds for PTSD, and (2) whether EMDR
can be used to directly ameliorate symptoms of psychosis. Our interven-
tionwas adapted from previous work (van den Berg, van der Vleugel, Star-
ing, de Bont, & de Jongh, 2013) and consists of a 16-session manualized
EMDR intervention specifically modified to target distressing psychotic
symptoms in out-patients with early psychosis. The intervention was
developed from pilot work with first episode psychosis clients indicating
clinically significant improvements in psychotic symptoms, trauma-related
symptoms, anxiety and depression (Ward-Brown et al., 2018). Participants
experienced therapy as highly acceptable and helpful, their feedback being
used to refine the approach further. The present investigation will exam-
ine whether it is feasible to conduct a larger-scale evaluation of “EMDR
for psychosis” (EMDRp). The results of this workwill be used to inform the
design of the future trial, including necessary sample size calculations for a
definitive efficacy and cost-effectiveness assessment. It is anticipated that
the future trial would focus on the reduction of psychotic symptoms as a
primary outcome, with secondary outcomes including trauma symptoms.
However, in order to ensure feasibility, a preliminary trial is required
before engaging in the large-scale programme.
2 | AIMS
To evaluate the feasibility and acceptability of conducting a definitive
trial of EMDRp in people with early psychosis. Feasibility will be
ascertained across a range of critical parameters, including: recruit-
ment and randomization rate, therapy engagement, assessment
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retention and therapy fidelity (see Table 1). Acceptability will be
ascertained by qualitative investigations with professionals and
service-user participants who have received the EMDRp therapy
intervention. Examination of the completeness of outcome measures
and variance in outcomes will be used to inform the design and power
calculation of a future definitive trial.
3 | METHODS
3.1 | Design
The EASE trial (“Eye movement desensitization and reprocessing therapy
in early psychosis: A feasibility randomized controlled trial”,
ISRCTN16262847) is a single-blind, parallel group randomized controlled
trial with random allocation to one of two arms; EMDRp alongside TAU
versus TAU alone. Allocation will be assigned at a ratio of 1:1 and will be
concealed from the assessing research assistants (RAs). Participants in
both arms will complete assessments at baseline, 6 and 12 months post-
randomization. Two qualitative studies will be nested within the trial,
one exploring the service user participants' views concerning acceptabil-
ity and impact of the intervention, and the other exploring the views of
professionals regarding implementation of EMDRp within services.
3.2 | Participants
The trial will comprise of 60 individuals with first episode psychosis
and a history of trauma. Inclusion criteria are listed in Table 2.
The recruitment target was informed by feasibility trials guide-
lines (Arain, Campbell, Cooper, & Lancaster, 2014; Eldridge
et al., 2016; Lancaster, Dodd, & Williamson, 2004) and will enable the
TABLE 1 Feasibility outcomes of the EASE trial
Criterion Critical feasibility outcome
Other feasibility and
acceptability data relevant to




consented into the trial and
randomized






Reasons for non-eligibility or
withdrawal of interest
*Feasibility will be demonstrated where an average of at least
three participants are recruited and randomized per month
**If at least two participants are recruited per month, then a
future trial will be feasible but additional strategies must be
identified to support recruitment (e.g., informed by other
feasibility data relevant to this criterion)
***If an average of one participant is recruited per month over
the recruitment period (<20 participants), feasibility within
the current design will not be demonstrated
(2) Therapy
engagement
% who drop-out of therapy/%
who did not receive
treatment allocated
Session record forms for each
therapy session
Number of therapy sessions
attended
Qualitative interviews with SU
participants
*Feasibility will be demonstrated if at least 70% of the
participants in the intervention arm completed at least 8
out of the 16 sessions of EMDRp
**If 50–70% of participants in the intervention arm complete
at least 8 out of the 16 sessions of EMDRp
***If less than 50% of participants in the intervention arm
complete at least 8 out of 16 sessions of EMDRp
(3) Assessment
retention
% of participants who are lost
to follow-up at end-of-
treatment and follow-up
assessment points
Reasons for withdrawal from
the study
Qualitative interviews with SU
participants
*If at least 70% of participants are retained and the end-of-
treatment and follow-up assessments, feasibility will be
demonstrated
**If 30–70% of participants are retained at the end-of-
treatment and follow-up assessments, a future trial will be
feasible if strategies to overcome barriers are identified
(e.g., via other data relevant to this criterion)
***If less than 30% of participants are retained at the end-of-
treatment and follow-up assessments, feasibility within the





Session record form for each
therapy session (including
reasons for deviation from
protocol)
*Feasibility will be demonstrated if over 80% of rated therapy
tapes will be rated as acceptable
**If 50–80% of rated therapy tapes will be rated as
acceptable, a future trial will be feasible if strategies to
overcome identified barriers (e.g., exploring the reasons for
deviation from protocol recorded in the therapist checklists)
***If less than 50% of rated therapy tapes will be rates as
acceptable, feasibility within the current design will not be
demonstrated
Note: * = Continue to main study without modifications—feasible as it is; ** = Continue but modify protocol—the future definitive trial is feasible with
modifications. *** = Stop—future definitive trial is not feasible.
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estimation of recruitment and retention parameters as well as the var-
iance of outcome measures. Recruitment will take place across Early
Intervention (EI) teams in the North West of England. The trial will be
introduced to potential participants by their usual care team. Informed
consent will be obtained by trained research assistants (RAs) prior to
confirming eligibility via the Trauma Screening Questionnaire and the
Positive and Negative Syndrome Scale (Table 2).
3.2.1 | Randomization
Participants will be randomly allocated (1:1 ratio) to either EMDRp +
TAU, or TAU alone by an unblinded member of the research team (the
principal investigator, the trial manager or the trial statistician) using
an online pseudo-random list with random permuted blocks of varying
sizes. Allocation will be concealed from the RAs conducting
assessments.
4 | INTERVENTION
EMDR is a trauma-focused therapy in which memories of traumatic
experiences are reprocessed to decrease the distress caused by them
and change the dysfunctional beliefs and perceptual associations
related to the traumatic event. This is achieved through an eight-
phase treatment protocol addressing past memories, present triggers
and future templates. Treatment phases are outlined in Table 3.
Phases do not correspond to specific therapy sessions; multiple
phases (usually phases 3–7) can be executed sequentially within the
same session. Typically, an EMDR session lasts from 60 to 90 minutes
with treatment generally lasting between 8 and 12 sessions. However,
more sessions are recommended in the context of complex mental
health presentations and severe/multiple trauma histories
(NICE, 2018).
The intervention offered in the current trial will be entirely con-
sistent with the eight phases of the standard EMDR protocol but the
focus of certain EMDR phases have been modified and expanded
(most notably phases 2 and 3, pertaining to client preparation and the
assessment and selection of suitable targets for subsequent
reprocessing work). This accounts for specific issues related to the
experience of psychotic symptoms and their impact on the client's
wellbeing. The treatment protocol builds on specific adaptations
already suggested in the application of EMDR to the treatment of psy-
chosis (e.g., van den Berg et al., 2013), but represents the first attempt
to deliver a manualized intervention that systematically implements
these psychosis-specific adaptations. These adaptations involve the
inclusion of:
1. a more explicit focus on structure and containment within sessions
to safely adhere to the limit of up to 16 sessions provided as part
of this feasibility trial. This is achieved through maintaining a clear
strand of goal-orientated focus throughout therapy, centring on
clients' most distressing present-day challenges and linking this
back to and working through related distressing/traumatic experi-
ences, to help progress towards achieving chosen therapeutic
goals
2. an enhanced focus on psychoeducation, grounding and client prep-
aration techniques—designed to enable successful reprocessing of
traumatic memories including those associated with dissociation
(a common concomitant of psychotic experiences; Pilton, Varese,
Berry, & Bucci, 2015), concurrent acute psychotic symptoms and
related difficulties (e.g., inattention). This may include an enhanced
TABLE 2 Participant inclusion and exclusion criteria
Inclusion
criteria
1. Aged at least 16 years
2. Capacity and willingness to provide informed consent
3. a. ICD diagnosis of schizophrenia-spectrum disorders (ICD codes F20, F22, F23, F25, F28, F29; ICD-11 codes 6A20, 6A21,
6A23, 6A24, 6A2Y,6A2Z)
b. or criterion level of positive symptoms severity, indicated by a score > 3 (symptom present) on the delusions (P1),
hallucinations (P3), grandiosity (P5) or suspiciousness (P6) items of the PANSS in the previous week
c. and/or the psychosis transition criteria of the CAARMS
4. In contact with mental health services, and have an assigned care-coordinator
5. Within 3 years from psychosis onset
6. Judged by the assigned care-coordinator/responsible clinician as clinically stable (no treatment change in the previous month,
not acutely suicidal and no suicide attempt in the previous 2 months)
7. Reporting at least 1 traumatic event on the TSQ, and at least subsyndromal post-traumatic symptoms in the previous week
(scores >0 on items 3_1 to 3_5 of the TSQ)
Exclusion
criteria
Primary diagnosis of substance/alcohol dependence, intellectual disability or cognitive dysfunction, as provided by the participant
care-coordinator/clinical team
Non-English speaking or requiring an interpreter for the intervention (the therapy and assessment battery at present can only be
delivered in English)
Receipt of EMDR from a qualified psychological therapist in accordance with NICE guidelines for PTSD (National Institute for
Health and Clinical Excellence, 2018) in the past 12 months
Note: Key: CAARMS = Comprehensive Assessment of At-Risk Mental States (Yung et al., 2005); EMDR = Eye Movement Desensitization and
Reprocessing Therapy; ICD = the International Classification of Disease; PANSS = Positive and Negative Syndrome Scale (Kay, Fiszbein, & Opler, 1987);
TSQ = Trauma Screening Questionnaire (de Bont et al. 2015).
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preparation phase, using tools such as the Constant Installation of
Present Orientation and Safety technique (CIPOS; Luber, 2009)
and enhanced practice of EMDR-related resource building and
visualization exercises, with a specific focus on psychosis-related
challenges or barriers in therapy (such as paranoia and hearing
voices)
3. assessment and therapeutic work around trauma symptoms that
may not reach diagnostic threshold for PTSD, to familiarize partici-
pants with the EMDR approach before targeting more complex
trauma memories or psychosis-related traumatic experiences;
4. traumatic experiences that preceded or precipitated the onset of
illness (and which may be thematically linked to psychotic symp-
toms; e.g., Hardy et al., 2005)
5. the traumatic impact of the psychotic episode itself (a source of
considerable traumatic stress in many first episode psychosis
patients; Berry, Ford, Jellicoe-Jones, & Haddock, 2013; Wilson,
Becker, & Tinker, 1997)
6. the impact of adverse life experiences and circumstances that
might have exacerbated maladaptive appraisals about psychotic
experiences as well as negative beliefs about the self and others
that are common in people with psychosis and are associated with
distress and impairment in this client group (Garety, Kuipers, Fow-
ler, Freeman, & Bebbington, 2001; Morrison, 2001)
The treatment will be delivered by EMDR therapists who have
experience in working with people with psychosis and/or PTSD. All
therapists will receive an initial 3-day training workshop in our
EMDRp protocol and will attend fortnightly group supervision
sessions.
4.1 | Treatment fidelity
Using the Modified EMDR Fidelity Checklist (Cooper, Smith, Lewis,
Lee, & Leeds, 2019) an EMDR consultant will rate a random selection
of therapy recordings (3–5 sessions per therapist) to ensure adher-
ence to EMDR when delivering our protocol. After each therapy ses-
sion, therapists will also complete a standardized session record form
to monitor session content; these will be reviewed during monthly
supervision meetings to maximize treatment fidelity throughout the
trial.
4.2 | Comparator
TAU will be in line with all standard and individually prescribed clin-
ical interventions as directed by clinical guidelines for psychosis
(NICE, 2014) and the participants' clinical team, and may include
antipsychotic medications and/or psychological interventions.
Although EMDR is not routinely employed in the treatment of psy-
chosis, TAU participants with comorbid PTSD may be referred by
their clinical teams to other services to receive a trauma-focused
interventions (TF-CBT or EMDR). For ethical reasons, the care
teams will not be asked to withhold such referrals/interventions.
Instead, the care received by TAU participants will be monitored
carefully through case notes reviews after the 12-month
assessment.
4.3 | Outcomes
This trial is designed to evaluate the feasibility of conducting a future
definitive trial. Therefore, the data collected at baseline and follow-up
assessments are intended to evaluate the feasibility of completing the
battery of measures to be employed in the future trial. At both base-
line and follow-up assessments, we will administer several measures
assessing psychotic symptoms, trauma symptoms, anxiety, depression,
functioning, service-user defined recovery as well as quality of life
and service usage data to inform future heath economics analyses
(Table 4).
TABLE 3 Standard EMDR treatment protocol phases (Shapiro, 2001)
Phase Details of EMDR protocol
1 History Taking (including discussion of the rationale for therapy and case conceptualization/idiographic formulation of the client's
difficulties)
2 Preparation (preparation for reprocessing of target trauma memories and equipping clients with strategies to better self-regulate during
trauma reprocessing work)
3 Assessment (the identification of a specific target memory/image as well as associated negative cognitions, disturbing emotions or bodily
sensations; a positive cognition that is preferable to the negative one is also identified)
4 Desensitization and Reprocessing (involving the repetitive use of bilateral stimulation, for example, the tracking of a moving object, while the
client is asked to simultaneously focus on the image, the negative cognition, and the disturbing emotion or body sensation until he/she
reports a marked reduction in distress associated with these experiences)
5 Installation (in which the client is encouraged to associate the trauma memory with the positive cognition previously identified, or a new
more adaptive positive cognition)
6 Body scan (designed to target any residual negative/uncomfortable physical sensation or bodily tension associated with the trauma memory)
7 Closure (generally involving the use of distress management and tolerance strategies before the end of the session)
8 Re-evaluation (where the client and therapist re-assess the previous target to evaluate whether additional work is necessary before
proceeding further with the intervention)
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5 | ANALYSIS
Descriptive statistics will be used to summarize assessments of feasi-
bility and acceptability in terms of the primary outcomes (Table 1).
Further descriptive information on the flow of participants across the
trial will be provided in accordance with relevant CONSORT fields for
feasibility trials (Eldridge et al., 2016). These will include: (1) number
of referrals received per month, (2) source of recruitment, (3) number
of participants contacted, (4) number of participants assessed for eligi-
bility, (5) number of participants consented into the trial and
TABLE 4 Summary of measures used to assess participant symptoms across three time points
Demographic information Baseline 6 months 12 months
Age, sex, ethnicity, employment status and occupation (if relevant), marital status, education level, self-
reported diagnosis, time since first episode of psychosis, duration of Early Intervention service input,
number and reasons for past psychiatric hospitalizations, current prescribed medications for mental health
difficulties (including dosage), diagnosis.
X Updated as required
Psychosis-related measures
PANSS The most widely used research measure to assess the severity of positive and
negative symptoms of psychosis as well as symptoms of general
psychopathology.
X X X
PSYRATS A semi-structured interview completed alongside the PANSS to provide a more
fine-grained assessment of auditory hallucinations and delusions, including
measures of subjective distress caused by these symptoms.
X X X
GPTS A brief self-report questionnaire assessing paranoid thinking and persecutory
delusions.
X X X
VIS A questionnaire assessing a range of positive and negative consequences of
voices (i.e., auditory verbal hallucinations) on various domains
X X X
QPR A service user-defined measure of subjective recovery from psychosis. X X X
Trauma-related measures
TSQ A brief measure used to screen for trauma exposure and post-traumatic stress
symptoms. In the present study, the modified version of the TSQ developed
by de Bont et al. (2015) for use in people with psychosis will be used to
check the participants' potential eligibility in this trial
X
TALE A measure specifically designed to assess exposure to adverse and traumatic
life experiences that are commonly reported by people with psychosis.
X
PCL-5 A self-report questionnaire assessing the presence and severity of post-
traumatic symptoms.
X X X
ITQ A brief measure assessing the severity of symptoms of PTSD and complex
PTSD as defined in the recently published ICD-11.
X X X
DES-II A self-report measure of dissociation. X X X
Health economic measures
EQ-5D-5L A health status questionnaires used in health economics analyses. X X X
EPQ An adapted version of the EPQ for specific use in early intervention for
psychosis services.
X X X
Other mental health and functioning measures
GAD-7 A brief and widely used questionnaires assessing symptoms of anxiety. X X X
PHQ-9 A brief and widely used questionnaires assessing symptoms of depression. X X X
PSP A scale assessing patients' functioning in four areas (socially useful activities,
personal and social relationships, self-care and disturbing/aggressive
behaviours).
X X X
QPR A service user-defined measure of subjective recovery from psychosis. X X X
Note: Key: DES-II = The Dissociative Experiences Scale-II (Carlson & Putnam, 1993); EPQ = Economic Patient Questionnaire (Davies et al., 2007); EQ-5D-
5L = The EuroQol 5-Dimension 5-Level measure (Janssen et al., 2013); GAD-7 = The Generalized Anxiety Disorder Questionnaire (Spitzer, Kroenke,
Williams, & Löwe, 2006); GPTS = Green Paranoid Thoughts Scale (Green et al., 2008); ITQ = International Trauma Questionnaire (Cloitre et al., 2018);
PANSS = Positive and Negative Syndrome Scale (Kay et al., 1987); PCL-5 = The PTSD Checklist for DSM-5 (Blevins, Weathers, Davis, Witte, &
Domino, 2015); PHQ-9 = The Patient Health Questionnaire (Kroenke, Spitzer, & Williams, 2001); PSP = The Personal and Social Performance Scale
(Morosini, Magliano, Brambilla, Ugolini, & Pioli, 2000); PSYRATS = The Psychotic Symptoms Rating Scales (Haddock, McCarron, Tarrier, & Faragher, 1999);
QPR = The Questionnaire about the Process of Recovery (Neil et al., 2009); TALE = The Trauma and Life Events checklist (Carr, Hardy, & Fornells-
Ambrojo, 2018); TSQ = The Trauma Screening Questionnaire (de Bont et al., 2015); VIS = The Voices Impact Scale (Strauss, n.d.).
VARESE ET AL. 1229
randomized, (6) reasons for non-eligibility or withdrawal of interest,
(7) retention of participants between baseline, end-of-treatment and
follow-up assessment periods, discriminating between participants
who did not receive the treatment allocated and individuals lost to
follow-up, (8) all important harms or unintended effects, and (9) the
completeness of participant's responses on all self-reports. Data on all
self-report and researcher-administered outcome measures will be
examined for completeness. No formal hypothesis testing will be car-
ried out comparing the two groups for clinical effectiveness. However,
outcome measures will be summarized by arm and standard devia-
tions will be estimated to inform the design of a future trial. Estima-
tion of the integrity of the intervention will rely on descriptive
analyses of the EMDR fidelity checklists and data from therapy ses-
sion record forms. This will inform training and supervision provision
of the future definitive trial.
5.1 | Qualitative studies
One month following their 6-month post-randomization (end of treat-
ment) assessment, participants in the EMDRp + TAU arm will be
invited to complete a qualitative interview. Consistent with previous
work (Awenat et al., 2017), we will use purposive sampling to recruit a
wide range of participants, based upon demographics and therapy
experiences (e.g., by recruiting participants with poor vs. good treat-
ment response). Semi-structured interviews conducted a researcher
unblinded to treatment allocation will be audio-recorded and tran-
scribed. Inductive Thematic Analysis (Braun & Clarke, 2013) will be
used to extract themes relating to experiences of participating in the
trial and undergoing EMDRp.
Also consistent with previous work (Awenat et al., 2017), we will
also recruit approximately 20 professionals (dependent upon theoreti-
cal sufficiency) whose role would impact either on participant referral
to the trial ('gatekeepers') and the commissioning, service/treatment
delivery and/or management of psychological therapies for psychosis.
Purposive sampling will facilitate recruitment of wide range of profes-
sional backgrounds from across healthcare organizations and relevant
services (e.g., commissioners; therapy services managers; EI care co-
ordinators, clinical psychologists and psychiatrists). These interviews
will cover questions relevant to the future implementation of EMDRp,
including their stakeholders' views on their understanding, views and
concerns about EMDR and the perceived barriers to implementing
EMDRp in EI services, alongside solutions to such barriers/problems.
All interviews will be audio recorded, transcribed verbatim and ana-
lyzed using inductive thematic analysis.
6 | DISCUSSION
The impact of trauma and the management of trauma-related symp-
toms in people with psychosis is a recognized research priority
(NICE, 2014). The overarching aim of this trial is to determine the fea-
sibility of running a definitive trial of EMDRp within EI services. The
delivery of such trials is vital to improving outcomes for those
affected by early psychosis and trauma. The application of trauma-
focused therapies to the treatment of psychosisis in its infancy.
However, based on extensive evidence linking trauma sequelae to
psychotic symptoms (Williams et al., 2018), it is possible that EMDRp
may have direct effects on psychotic symptoms. Our feasibility data
will allow evaluation of the likely levels of recruitment and retention
into a future larger-scale trial. The project will also enable the evalua-
tion of the acceptability of EMDRp by considering levels of therapy
engagement, the qualitative feedback from participants allocated to
receive EMDRp, and the extent to which EMDR therapists can deliver
our EMDRp protocol with high level of fidelity.
Several trials have recently been conducted to evaluate the effi-
cacy of trauma-focused therapy in people with psychotic disorders
(e.g., Brand, McEnery, Rossell, Bendall, & Thomas, 2018). The present
trial is distinguished in that the primary focus is the evaluation of a
treatment protocol aimed at improving psychotic symptoms rather
than co-morbid PTSD. Although previous trials have predominantly
focused on participants who have been living with psychosis for many
years (e.g., van den Berg et al., 2015), our trial specifically considers
individuals with early psychosis who receive support from EI services.
Access to effective treatment in the first few years following the
onset of psychosis is a crucial determinant of future clinical and func-
tional outcomes (Bird et al., 2010). The findings of our trial and the
future definitive evaluation informed by the present trial will confirm
whether trauma-focused therapies could augment existing evidence-
based treatment options for early psychosis, and should, therefore, be
offered routinely to clients supported by EI services. Our EMDRp
intervention was developed from previous clinical recommendations
for adapting the delivery of EMDR to people with distressing psycho-
sis (van den Berg et al., 2013) and with input from 'experts-by-experi-
ence' who took part in case studies of trauma-focused therapy in
early psychosis conducted by members of our team (Ward-Brown
et al., 2018; Ward-Brown & Keane, 2019). A further strength is that
the design of the trial has been developed in collaboration between
academic researchers, frontline trauma therapists and experts-by-
experience, hopefully ensuring the development of a “real-world”,
practical and effective intervention which improves outcomes for
those affected by psychosis and experiences of trauma and could be
implemented in future clinical practice in a sustainable and
effective way.
There are several limitations to the study. First, our feasibility trial
does not have an active control treatment arm, so our findings will be
silent regarding the potential effectiveness of EMDRp relative to
other psychosocial interventions with an established evidence-base
for the treatment of psychosis, or other trauma-focused therapies.
Second, this early stage evaluation is unlikely to shed light on the
mechanisms of action of EMDR when applied to the treatment of
trauma-related difficulties reported by people with psychosis. Both
limitations could be addressed in the future definitive trial through the
selection of evidence-based psychosocial comparators (e.g., Cognitive
Behavioural Therapy for psychosis; NICE, 2014) and the integration of
research methods to evaluate mechanisms of efficacy of complex
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mental health interventions (e.g., Dunn et al., 2015), a line of research
that could be informed by the growing evidence on the potential
mediators of the trauma-psychosis relationship (Williams et al., 2018)
and the neural and psychological mechanisms of action of EMDR in
other patient groups (e.g., Landin-Romero, Moreno-Alcazar, Pagani, &
Amann, 2018).
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